The effect size and enduring benefit of MDMA in PTSD has surpassed all expectation in Phase 3 trials
It is possible this agent may be approved by the FDA pending the results of the second Phase 3 trial which is now underway



Host: Dr David Lim | Total time: 40 mins

Guest: Rick Doblin, Founder and Executive Director; the Multidisciplinary Association for Psychedelic Studies (MAPS)


Register for our fortnightly FREE WEBCASTS

Every second Tuesday | 7:00pm-9:00pm AEST

Click here to register for the next one

<ul>
<li>The effect size and enduring benefit of MDMA in PTSD has surpassed all expectation in Phase 3 trials</li>
<li>It is possible this agent may be approved by the FDA pending the results of the second Phase 3 trial which is now underway </li>
</ul>
Host: Dr David Lim | Total time: 40 mins
Guest: Rick Doblin, Founder and Executive Director; the Multidisciplinary Association for Psychedelic Studies (MAPS)
 Register for our fortnightly FREE WEBCASTS
Every second Tuesday | 7:00pm-9:00pm AEST
<a href="https://www.healthed.com.au/webcast/">Click here to register for the next one</a>

Healthed's medical education channel features the latest high quality clinical interviews and lectures from leading experts in their field, offering health professionals a convenient new way to boost their knowledge.

Advertisement